[{"id":"62c4f641-e07b-4061-a840-4410a2fd80ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05980416","created_at":"2023-08-08T14:08:21.220Z","updated_at":"2024-07-02T16:35:16.049Z","phase":"Phase 1","brief_title":"Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2","source_id_and_acronym":"NCT05980416","lead_sponsor":"Elevation Oncology","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-06"},{"id":"f8f53ebe-73d9-402d-b333-b23802618040","acronym":"","url":"https://clinicaltrials.gov/study/NCT05043987","created_at":"2021-09-14T16:53:27.314Z","updated_at":"2024-07-02T16:35:37.794Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers","source_id_and_acronym":"NCT05043987","lead_sponsor":"Conjupro Biotherapeutics, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2023-09-07"},{"id":"de3ef43b-b7ce-4ca6-821c-63d13927851a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009966","created_at":"2021-08-18T15:53:40.109Z","updated_at":"2024-07-02T16:36:22.492Z","phase":"Phase 1","brief_title":"Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor","source_id_and_acronym":"NCT05009966","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-10-25"}]